PRECLINICAL EFFICACY OF A PROTOTYPE DNA VACCINE - ENHANCED PROTECTION AGAINST ANTIGENIC DRIFT IN INFLUENZA-VIRUS
PRECLINICAL EFFICACY OF A PROTOTYPE DNA VACCINE - ENHANCED PROTECTION AGAINST ANTIGENIC DRIFT IN INFLUENZA-VIRUS
复制标题
DOI：
10.1038/nm0695-583
复制
发表时间：
1995-06-01
期刊：
影响因子：
82.9
通讯作者：
LIU, MA
中科院分区：
文献类型：
--
作者：
DONNELLY, JJ;FRIEDMAN, A;LIU, MA
用编码外源蛋白质的质粒DNA表达载体进行疫苗接种可激发抗体和细胞介导的免疫，并在动物模型中预防疾病。我们报告了DNA疫苗的比较，使用当代人类病毒株，和临床许可（灭活病毒或亚病毒粒子）疫苗在临床前动物模型，以更好地预测其在人类中的疗效。流感DNA疫苗在非人灵长类动物和雪貂中均引起抗体，并且比当代临床许可的疫苗更有效地保护雪貂免受抗原性不同的流行性人流感病毒的攻击。这些研究表明，DNA疫苗可能比灭活病毒或亚病毒体疫苗更有效，特别是针对不同的病毒株。
Vaccination with plasmid DNA expression vectors encoding foreign proteins elicits antibodies and cell-mediated immunity and protects against disease in animal models. We report a comparison of DNA vaccines, using contemporary human strains of virus, and clinically licensed (inactivated virus or subvirion) vaccines in preclinical animal models, to better predict their efficacy in humans. Influenza DNA vaccines elicited antibodies in both non-human primates and ferrets and protected ferrets against challenge with an antigenically distinct epidemic human influenza virus more effectively than the contemporary clinically licensed vaccine. These studies demonstrate that DNA vaccines may be more effective, particularly against different strains of virus, than inactivated virus or subvirion vaccines.